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Efficacy of Antimicrobial Treatments and Vaccination Regimens for
Control of Porcine Reproductive and Respiratory Syndrome Virus and
Streptococcus suis Coinfection of Nursery Pigs
Abstract
Seventy-six, crossbred, porcine reproductive and respiratory syndrome virus (PRRSV)-free pigs were weaned
at 12 days of age and randomly assigned to seven groups of 10 to 11 pigs each. Pigs in group 1 served as
unchallenged controls. Pigs in groups 2 to 7 were challenged intranasally with 2 ml of high-virulence PRRSV
isolate VR-2385 (104.47 50% tissue culture infective doses per 2 ml) on day 0 of the study (30 days of age).
Seven days after PRRSV challenge, pigs in groups 2 to 7 were challenged intranasally with 2 ml of Streptococcus
suis serotype 2 (108.30 CFU/2 ml). Group 2 pigs served as untreated positive controls. Antimicrobial
treatments included daily intramuscular injection with 66,000 IU of procaine penicillin G per kg of body
weight on days 8 to 10 (group 3), drinking water medication with 23.1 mg of tiamulin per kg during days 8 to
10 (group 4), and daily intramuscular injection of 5.0 mg of ceftiofur hydrochloride per kg on days 8 to 10
(group 5). Vaccination regimens included two intramuscular doses of an autogenous killedS. suis vaccine
(group 6) prior to S. suischallenge or a single 2-ml intramuscular dose of an attenuated live PRRSV vaccine
(group 7) 2 weeks prior to PRRSV challenge. Mortality was 0, 63, 45, 54, 9, 40, and 81% in groups 1 to 7,
respectively. Ceftiofur treatment was the only regimen that significantly (P < 0.05) reduced mortality
associated with PRRSV and S. suis coinfection. The other treatments and vaccinations were less effective. We
conclude that ceftiofur administered by injection for three consecutive days following S. suis challenge was the
most effective regimen for minimizing disease associated with PRRSV and S. suiscoinfection.
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Seventy-six, crossbred, porcine reproductive and respiratory syndrome virus (PRRSV)-free pigs were weaned
at 12 days of age and randomly assigned to seven groups of 10 to 11 pigs each. Pigs in group 1 served as
unchallenged controls. Pigs in groups 2 to 7 were challenged intranasally with 2 ml of high-virulence PRRSV
isolate VR-2385 (104.47 50% tissue culture infective doses per 2 ml) on day 0 of the study (30 days of age). Seven
days after PRRSV challenge, pigs in groups 2 to 7 were challenged intranasally with 2 ml of Streptococcus suis
serotype 2 (108.30 CFU/2 ml). Group 2 pigs served as untreated positive controls. Antimicrobial treatments
included daily intramuscular injection with 66,000 IU of procaine penicillin G per kg of body weight on days
8 to 10 (group 3), drinking water medication with 23.1 mg of tiamulin per kg during days 8 to 10 (group 4), and
daily intramuscular injection of 5.0 mg of ceftiofur hydrochloride per kg on days 8 to 10 (group 5). Vaccination
regimens included two intramuscular doses of an autogenous killed S. suis vaccine (group 6) prior to S. suis
challenge or a single 2-ml intramuscular dose of an attenuated live PRRSV vaccine (group 7) 2 weeks prior to
PRRSV challenge. Mortality was 0, 63, 45, 54, 9, 40, and 81% in groups 1 to 7, respectively. Ceftiofur treatment
was the only regimen that significantly (P < 0.05) reduced mortality associated with PRRSV and S. suis
coinfection. The other treatments and vaccinations were less effective. We conclude that ceftiofur administered
by injection for three consecutive days following S. suis challenge was the most effective regimen for minimizing
disease associated with PRRSV and S. suis coinfection.
Field evidence strongly suggests that PRRSV infection
makes pigs more susceptible to bacterial diseases in nursery
and grow-finish pigs (2). Combined porcine reproductive and
respiratory syndrome virus (PRRSV) and Streptococcus suis
infections are common (10, 14, 16) and can be especially prob-
lematic to control with conventional medication and vaccina-
tion regimens (1, 15). Models to study the pathogenesis and
control of PRRSV and S. suis coinfection have recently been
described (4, 14). Our coinfection model uses 2- to 4-week-
old conventional pigs which are inoculated intranasally with
PRRSV, followed 7 days later by intranasal inoculation with
S. suis (14). In this model, we demonstrated that pigs infected
with the high-virulence VR-2385 strain of PRRSV exhibit
more frequent and severe clinical central nervous system
(CNS) disease and lesions typical of S. suis infection, have
more widespread tissue dissemination of S. suis, and expe-
rience significantly higher mortality than pigs infected with
S. suis alone. We believe that the model mimics what occurs in
the field, making it an ideal model to test the efficacy of control
and treatment regimens. The objective of the study reported
here was to measure the efficacies of several commonly used
control and treatment protocols for minimizing losses associ-
ated with PRRSV and S. suis coinfection of nursery pigs.
MATERIALS AND METHODS
Experimental design. The study was approved by the Iowa State University
Committee on Animal Care and Use. Seventy-six, crossbred, PRRSV-free pigs
were weaned at 12 days of age and moved to an isolated facility. The pigs were
randomly assigned to seven groups of 10 to 11 pigs each (Table 1). Pigs in group
1 served as unchallenged negative controls. Pigs in the remaining groups (2 to 7)
were challenged intranasally with 2 ml of high-virulence PRRSV isolate VR-2385
on day 0 of the study (30 days of age). Seven days after PRRSV challenge, pigs
in groups 2 to 7 were challenged intranasally with 2 ml of S. suis serotype 2,
isolate ISU VDL 40634/94.
Pigs in group 2 served as untreated, dually inoculated controls. Pigs in group
3 were treated by intramuscular injection with 66,000 IU of procain penicillin G
(Pfi-Pen G; Pfizer Animal Health, New York, N.Y.) per kg of body weight on
days 8, 9, and 10. Pigs in group 4 received 23.1 mg of tiamulin (Denegard;
Boehringer Ingelheim Animal Health, Inc., St. Joseph, Mo.) per kg per pig per
day in the drinking water on days 8, 9, and 10. Pigs in group 5 were treated by
intramuscular injection with 5.0 mg of ceftiofur hydrochloride (Excenel; Phar-
macia & Upjohn, Kalamazoo, Mich.) per kg on days 8, 9, and 10. Pigs in group
6 received two intramuscular doses of a commercially prepared autogenous S.
suis vaccine prior to S. suis challenge. The S. suis vaccine was prepared from the
same isolate used for challenge, was formaldehyde inactivated, and was in Emul-
sigen and aluminum hydroxide adjuvants (MVP Laboratories Inc., Ralston,
Nebr.). Pigs in group 7 received a single 2-ml intramuscular dose of attenuated
live PRRSV vaccine (RespPRRS/Repro; Boehringer Ingelheim Animal Health,
Inc.) 2 weeks prior to PRRSV challenge.
Inoculum preparation. PRRS challenge virus isolate VR-2385 was propagated
on MARC-145 cells and titrated by serial 10-fold dilutions in a 96-well microtiter
plate. The challenge virus was at the seventh passage in cell culture and had a
titer of 104.47 50% tissue culture infective doses/ 2 ml.
S. suis serotype 2, isolate ISU VDL 40634/94, was originally cultured from the
meninges of a nursery pig that was naturally infected with S. suis. The isolate was
passed by intravenous inoculation into a 3-week-old pig, which was euthanized
when it exhibited signs of CNS disease. The brain and meninges were collected
and homogenized, and aliquots of the homogenate were frozen at 270°C. The
bacterial challenge inoculum for this study was prepared by growing an aliquot
of the brain and meninges homogenate on bovine blood agar plates (BAPs)
overnight and then in Todd-Hewitt broth with 5% fetal calf serum for 7.25 h. The
* Corresponding author. Mailing address: Veterinary Diagnostic
Laboratory, College of Veterinary Medicine, Iowa State University,
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bacteria and growth media were diluted 1:10 with Hanks’ balanced salt solution
and given intranasally to pigs. Pigs were administered 108.30 CFU/2-ml dose
intranasally. The inoculum was checked for purity by streaking onto a BAP and
incubating at 37°C in 5% CO2 air.
The susceptibility of the challenge inoculum to the three antimicrobials was
determined by a microbroth dilution breakpoint susceptibility test (Sensititre;
Trek Diagnostic Systems, Inc., Westlake, Ohio) and by determination of the
MICs by microbroth dilution (Trek Diagnostic Systems, Inc.). The isolate was
susceptible to all of the antimicrobials used in this experiment at levels at or
below the lowest dilution tested. The isolate was found to be susceptible to
ceftiofur at ,1.0 mg/ml, tiamulin at ,8.0 mg/ml, and penicillin at ,0.03 mg/ml by
the microbroth dilution breakpoint susceptibility test. The isolate was found to
be susceptible to ceftiofur at ,0.50 mg/ml, tiamulin at ,4.0 mg/ml, and penicillin
at ,0.12 mg/ml by the MIC susceptibility test.
Clinical evaluation. Daily clinical respiratory disease scores, ranging from 0 to
6 (0 5 normal, 6 5 severe), were recorded on days 0 to 28 postchallenge with
PRRSV as previously described (5, 6). Other clinical observations, including
rectal temperatures, inappetence, lethargy, CNS signs, and swollen joints and
lameness (0 5 normal, 1 5 mild, 2 5 moderate, and 3 5 severe) were recorded
daily.
Gross and microscopic pathology examination. Pigs exhibiting severe CNS
disease (ataxia, prostration, or opisthotonus) or severe joint swelling and lame-
ness resulting in recumbence were euthanized immediately and necropsied.
Complete necropsies were performed on all remaining pigs on day 28 (28 days
after PRRSV and 21 days after S. suis challenge). An estimated percentage of the
lung with grossly visible pneumonia was recorded for each pig based on a
previously described PRRS lung lesion scoring scheme (5, 6). Sections for his-
topathologic examination were taken from nasal turbinate, lung, heart, brain,
lymph nodes, tonsil, thymus, liver, spleen, joints, and kidney. Sections of lung
were blindly examined microscopically and given a score for severity of intersti-
tial pneumonia (0 5 normal, 1 5 mild, 2 5 moderate, and 3 5 severe).
Serology and virus isolation. Blood was collected from all pigs at necropsy and
from all remaining live pigs on days 0, 7, 14, 21, and 28 postinoculation. Serum
antibodies to PRRSV were measured using the Herd Check PRRSV enzyme-
linked immunosorbent assay (IDEXX Laboratories, Westbrook, Mass.). Bron-
choalveolar lavage (BAL) was performed aseptically at necropsy using 50 ml of
lavage fluid consisting of minimal essential medium with antibiotics (9 mg of
gentamicin/ml, 100 U of penicillin G/ml, and 100 mg of streptomycin/ml). Lavage
fluid was gently dispensed and aspirated several times into the lungs. The BAL
fluid was kept at 270°C until PRRSV isolation was attempted on a confluent
monolayer of MARC-145 cells (11–13). Viral cytopathic effect was confirmed by
an indirect immunofluorescence assay (8). Monolayers were stained with anti-
PRRSV monoclonal antibody SDOW-17 (9) and fluorescein isothiocyanate-
conjugated anti-mouse immunoglobulin G (Sigma, St. Louis, Mo.) and then
viewed with a fluorescence microscope for evidence of specific viral antigens. If
cytopathic effect was not observed within 7 days, the cultures were frozen and
thawed and blindly passaged two more times before they were considered neg-
ative.
Bacteriology. Whole blood was collected in EDTA tubes and cultured on
BAPs and in Todd-Hewitt broth on days 7, 8, 9, and 10 from six randomly
selected pigs in each group. The upper respiratory tract (nasal cavity and tra-
chea), lungs, mandibular lymph node, pericardium, peritoneum, pleura, spleen,
liver, CNS (brain and meninges), and joints were swabbed and cultured for S. suis
serotype 2 at necropsy. A blood sample was taken from each animal at necropsy
and cultured for S. suis serotype 2. Swabs obtained at necropsy were immediately
streaked onto BAPs. All cultures were incubated at 37°C in 5% CO2 for 24 to
48 h. Alpha-hemolytic streptococcus-like colonies were tested for growth in 6.5%
NaCl and production of amylase (3). Representative colonies that did not grow
in NaCl and were positive for production of amylase were checked by coagglu-
tination to determine if they were S. suis serotype 2 (7).
Statistical analysis. Mortality and organism isolation data were analyzed by
Fisher’s exact test using a P of #0.05 as the level of significance for comparison.
Clinical scores and macroscopic and microscopic lesion scores were evaluated
by analysis of variance (ANOVA) using a completely randomized design with
the pig as the experimental unit. If the overall ANOVA result was significant
(P # 0.05), pairwise comparisons were performed by least-significant-difference
analysis.
RESULTS
Clinical evaluation. Respiratory disease, lameness, and CNS
disease scores are summarized in Table 2. Unchallenged, un-
treated (negative) control pigs remained normal throughout
the experiment. Between 3 and 7 days postinoculation (DPI)
with PRRSV, pigs in the PRRSV-challenged groups (2 to 7)
developed fevers (40.5 to 42°C) and exhibited respiratory dis-
ease characterized by rapid and labored respiration. At 7 DPI,
groups 2 to 7 were challenged with S. suis. Within 24 h of S. suis
challenge, at least 1 pig in each of groups 2 to 7 exhibited CNS
TABLE 1. Experimental design of control and treatment protocols for PRRSV and S. suis coinfection
Group No. ofpigs Challenge
a Treatment (codeb) Dose Routec Day(s) oftreatment
1 11 None None (NC)
2 11 PRRS and S. suis None (PC)
3 11 PRRS and S. suis Procaine penicillin G (Pfi-Pen G) (PEN) 66,000 IU/kg i.m. 8, 9, 10
4 11 PRRS and S. suis Tiamulin (Denagard) (TIA) 23.1 mg/kg p.o. 8, 9, 10
5 11 PRRS and S. suis Ceftiofur (Excenel) (CEF) 5.0 mg/kg i.m. 8, 9, 10
6 10 PRRS and S. suis Autogenous S. suis vaccine (SS VX) 2 ml i.m. 218, 24
7 11 PRRS and S. suis MLV PRRSV vaccine (RespPRRS/Repro) (PR VX) 2 ml i.m. 214
a PRRSV challenge on day 0, S. suis challenge on day 7.
b NC, negative controls; PC, positive controls; PEN, penicillin; TIA, tiamulin; CEF, ceftiofur; SS VX, S. suis vaccine; PR VX, PRRSV vaccine.
c i.m., intramuscular injection; p.o., per os via drinking water.
TABLE 2. Rectal temperature data and respiratory disease, CNS disease, and lameness scoresc
Group
(coded)
No. of days with mean rectal
temperatures over 40°C 6 SD
Mean respiratory
disease scorea Mean CNS disease score
b Mean lameness scoreb
1–11 DPI 12–28 DPI 1–11 DPI 12–28 DPI 1–11 DPI 12–28 DPI 1–11 DPI 12–28 DPI
1 (NC) 0.8 6 1.2 C 3.9 6 2.0 A 0.0 6 0.0 C 0.1 6 0.1 D 0.00 6 0.00 C 0.00 6 0.00 A 0.00 6 0.00 C 0.01 6 0.02 B
2 (PC) 7.0 6 3.9 A 1.5 6 1.3 A 2.1 6 0.4 A 1.4 6 0.1 B 0.14 6 0.18 A, B 0.00 6 0.00 A 0.49 6 0.42 A 0.63 6 0.16 A
3 (PEN) 3.7 6 3.1 B 3.7 6 2.8 A 2.2 6 0.3 A 1.4 6 0.1 B 0.10 6 0.17 B, C 0.01 6 0.03 A 0.38 6 0.34 A, B 0.71 6 0.28 A
4 (TIA) 4.5 6 1.7 B 2.6 6 2.2 A 2.1 6 0.2 A 1.5 6 0.2 B 0.12 6 0.13 A, B 0.01 6 0.03 A 0.25 6 0.23 B 0.37 6 0.26 A
5 (CEF) 4.8 6 2.9 A, B 4.5 6 4.0 A 1.8 6 0.3 B 1.0 6 0.5 C 0.02 6 0.04 B, C 0.01 6 0.02 A 0.28 6 0.21 A, B 0.50 6 0.58 A
6 (SS VX) 4.6 6 1.7 B 5.2 6 4.4 A 2.0 6 0.2 A 1.9 6 0.5 A 0.08 6 0.10 B, C 0.02 6 0.04 A 0.27 6 0.20 A, B 0.37 6 0.11 A
7 (PR VX) 3.6 6 2.5 B 0.0 6 0.0 A 2.0 6 0.2 A, B 2.1 6 0.2 A 0.22 6 0.20 A 0.00 6 0.0 A 0.45 6 0.16 A, B 0.32 6 0.15 A, B
a Respiratory disease scores (0 to 6; 0 5 normal, 6 5 severe) are reported as group means 6 standard deviations.
b CNS signs and lameness scores (0 to 3; 0 5 normal, 3 5 severe) are reported as means 6 standard deviations.
c Within each column, values followed by letters (A, B, C, and D) are significantly different from other values followed by a different letter(s) (P , 0.05).
d See Table 1 for an explanation of codes.
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disease signs such as head tilt, nystagmus, tremors, ataxia,
prostration, and opisthotonus. Antibiotic treatment was initi-
ated in groups 3 to 5 at 24 h after S. suis challenge.
Pigs exhibiting severe CNS disease (ataxia, prostration, or
opisthotonous) or severe joint swelling and lameness resulting
in recumbency were euthanized and recorded as mortalities.
Overall mortality and time of death or euthanasia are summa-
rized in Fig. 1. Pigs from the untreated positive control group
(group 2) died or were euthanized on days 8 (1 pig), 10 (1 pig),
11 (2 pigs), 13 (1 pig), 15 (1 pig), and 17 (1 pig), for an overall
mortality of 63%. Respiratory disease in group 2 was moderate
to severe from 8 to 16 DPI and mostly resolved by 28 DPI. The
majority of the pigs in this group exhibited mild-to-severe
lameness associated with swollen joints in the rear and front
legs from 8 to 20 DPI.
Levels of clinical disease severity and progression in the
penicillin (group 3)- and tiamulin (group 4)-treated groups
were similar. Respiratory disease was moderate to severe be-
tween 8 and 17 DPI and mostly resolved by 28 DPI. Three pigs
in each of groups 3 and 4 exhibited mild ataxia between 8 and
9 DPI. Joint swelling was present in the majority of the pigs in
these groups by 10 DPI. All of the pigs except one pig in group
4 clinically improved during the period of antibiotic adminis-
tration from 8 to 10 DPI. By 12 DPI, 48 h after antibiotic
treatments ceased, the incidence and severity of CNS disease
and lameness increased. Five pigs in each of groups 3 and 4
died or were euthanized between 12 and 17 DPI. Mild joint
swelling and lameness persisted in several pigs in both of these
groups through 28 DPI. Overall mortality was 45 and 54% in
the penicillin and tiamulin groups, respectively.
Ceftiofur treatment (group 5) was the only regimen that
significantly (P , 0.05) reduced mortality. Pigs in the ceftio-
fur-treated group remained the healthiest of the coinfected
groups. Respiratory disease severity and progression was sim-
ilar to those features of other PRRSV-infected groups. Ataxia
and head tilt were observed in 2 pigs between 8 and 9 DPI. At
17 DPI, one pig was found in opisthotonus and was euthanized.
This was the only pig in the ceftiofur group that had to be
euthanized (overall mortality, 9%) or died prior to the sched-
uled necropsy at 28 DPI. Joint swelling and lameness were
evident in the majority of the pigs by 10 DPI and became less
severe and prevalent following the antibiotic treatment. Mild
transient joint swelling and lameness recurred in several of the
pigs between 21 and 28 DPI.
Respiratory disease severity and progression in the S. suis-
vaccinated group (group 6) were similar to those of groups 2 to
5. Mild-to-severe joint swelling was observed in 9 of 11 pigs,
and CNS disease characterized by ataxia and head tilt was
observed in 5 of 11 pigs by 11 DPI. Three pigs were euthanized
at 11 DPI and one was euthanized at 15 DPI because of CNS
disease and/or severe lameness. Overall mortality was 40%.
Lameness resolved in the remaining pigs by 28 DPI.
The PRRSV-vaccinated pigs (group 7) remained clinically
normal prior to PRRSV challenge. Respiratory disease sever-
ity and progression subsequent to PRRSV challenge were sim-
ilar to those of unvaccinated groups 2 to 6. Nine pigs exhibited
tremors, ataxia, head tilt, and/or opisthotonus by 14 DPI.
Lameness associated with mild-to-severe joint swelling was
observed in 11 of 11 pigs by 11 DPI. Eight pigs were euthanized
due to CNS disease or recumbency associated with lameness
between 10 and 14 DPI. The nineth pig was euthanized at 21
DPI. Overall mortality was 81%. The CNS signs and lameness
resolved by 23 DPI in the remaining two pigs in this group.
Gross and microscopic lesions. PRRSV-induced gross le-
sions were characterized by mottled-tan, firm lungs and en-
larged, tan lymph nodes. PRRSV-induced gross lung lesions
were well developed by 10 DPI when the first pigs in groups
2, 4, and 7 died. Gross lung lesions were not present or were
in the resolving stages by 28 DPI. Microscopic examination
revealed mild-to-severe, multifocal, proliferative interstitial
pneumonia characteristic of PRRSV infection (5, 6). The on-
set, severity and progression of the microscopic lung lesions
were similar in groups 2 to 7. Fibrinosuppurative pleuritis was
observed in two pigs in group 2, one pig in group 3, and one pig
in group 6. Mild-to-moderate necrotizing and lymphoplasma-
cytic pulmonary arteritis was observed in 9 of 11 pigs in group
7. This lesion was not observed in any other group.
Fibrinosuppurative meningitis, synovitis, peritonitis, pericar-
ditis, and/or lymphadenitis typical of S. suis infection was ob-
served in a portion of the pigs in all PRRSV and S. suis dually
inoculated groups. Results are summarized in Table 3. Pigs in
group 2 (untreated positive controls) and group 7 (PRRSV
vaccinated) had the highest incidence (7 of 11 pigs) of suppu-
rative meningitis. Mild nonsuppurative encephalitis and myo-
carditis were observed in the majority of PRRSV-infected pigs
(data not shown).
Serology and virus isolation. PRRSV isolation results from
serum and BAL specimens are summarized in Table 4. All of
the PRRSV-challenged pigs, except one pig in group 4, were
viremic by 7 DPI. By 14 DPI, viremia was confirmed in all
PRRSV-challenged pigs. No treatment differences were ob-
served in the onset or incidence of viremia at 7 and 14 DPI.
Viremia was still present at 28 DPI in 0 of 11, 2 of 4, 1 of 6, 3 of
5, 0 of 10, 3 of 6, and 0 of 2 pigs in groups 1 to 7, respectively.
All of the PRRSV-challenged pigs became positive (S/P ratio,
.0.4) for PRRSV serum antibodies by 14 DPI (data not shown).
Bacteriology. Table 5 summarizes the isolation of S. suis
from blood and tissues. S. suis was isolated from the blood
FIG. 1. Survivability of PRRSV- and S. suis-coinfected pigs after vaccination
or antimicrobial treatment. See Table 1 for an explanation of the abbreviations.
TABLE 3. Microscopic lesion summaryc
Group
No. of pigs with microscopic lesionsa/
total no. of pigs in the group
Meningitis Synovitis Pl, Pt, Pcb Lymphadenitis
1 0/11 A 0/11 A 0/11 A 0/11 A
2 7/11 C 6/11 B, C 3/11 A 3/11 A, B
3 5/11 B, C 7/11 C 2/11 A 4/11 B
4 4/11 B, C 5/11 B, C 1/11 A 4/11 B
5 1/11 A, B 2/11 A, B 2/11 A 2/11 A, B
6 1/10 A, B 5/10 B, C 1/11 A 4/10 B
7 7/11 C 6/11 B, C 0/11 A 4/11 B
a Suppurative inflammation consistent with S. suis infection.
b Pl, Pt, and Pc, pleuritis, peritonitis, and pericarditis, respectively.
c Within each column, values followed by letters (A, B, C, and D) are signif-
icantly different from other values followed by a different letter(s) (P , 0.05).
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and/or internal tissues from all of the pigs in groups 2 to 6 that
were euthanized or died prior to the 28-DPI necropsy. We
were unable to recover S. suis from one pig in group 7 (Resp-
PRRS/Repro modified live-virus vaccine) that died at 13 DPI
(6 days postinoculation with S. suis). This pig had suppurative
lymphadenitis suggestive of bacterial infection; however, the
cause of death may have been associated with PRRSV in-
fection based on microscopic lesions consistent with severe
PRRSV-induced disease (nonsuppurative encephalitis, in-
terstitial pneumonia, and nonsuppurative myocarditis). S. suis
serotype 2 was isolated from the blood of 26 of 65, CNS
specimens (cerebrospinal fluid or meninges) of 24 of 65, pleura
or peritoneum or pericardial surfaces of 20 of 65, joints of 16
of 65, upper respiratory tracts of 11 of 65, and lungs of 11 of 65
of the pigs dually challenged with PRRSV and S. suis. S. suis
serotype 2 was recovered from the cerebrospinal fluid of one
control pig. Based on the lack of meningitis or other lesions
consistent with S. suis infection of this pig, we believe that this
isolate most likely is a procedural contaminant.
DISCUSSION
Coinfection of nursery pigs with PRRSV and S. suis is com-
mon and can be especially problematic to control with conven-
tional medication and vaccination protocols. Modern produc-
tion technologies such as segregated early weaning have failed
to control losses associated with PRRSV and S. suis coinfec-
tion in many herds. In order to address this problem we de-
veloped a model which mimics field cases of PRRSV and S.
suis coinfection. The coinfection model has allowed us to test
several control and treatment protocols that are commonly
used in the field. In this study, we found that intramuscular
injection of ceftiofur hydrochloride was the only protocol
among the five tested that significantly reduced mortality and
clinical disease associated with PRRSV and S. suis coinfection.
The treatment protocols selected for testing in this study
were based on protocols used by practicing veterinarians who
regularly submit swine cases to the Iowa State University Vet-
erinary Diagnostic Laboratory (ISU-VDL). Our results con-
firmed that two of the widely used antimicrobial treatment
regimens were not adequate. Based on case reports from sub-
mission to the ISU-VDL, penicillin is the most common drug
used for treatment of S. suis-associated diseases. Mortality in
the group treated with penicillin was 46% compared to 63% in
the untreated controls (P . 0.05). Most of the penicillin-
treated pigs improved in health status considerably during an-
tibiotic treatment; however, within 48 h after antibiotic treat-
ment ceased, the incidence and severity of CNS disease and
lameness increased and death losses continued. The mortality
in the tiamulin-water-medicated group was 54% compared to
63% for untreated controls (P . 0.05). Tiamulin is approved
for use in treatment of swine dysentery associated with Brachy-
spira hyodysenteriae and for the treatment of pneumonia due to
Actinobacillus pleuropneumoniae. Tiamulin is not approved for
use in treatment of S. suis-induced disease; however, case re-
ports indicate that it is sometimes used for this purpose. The
convenience of water medication, compared to injections, of-
ten facilitates better compliance with recommended treatment
protocols. There are no approved water medications for treat-
ment of S. suis infections; however, amoxicillin and cephalexin
are other medications that reportedly are sometimes used in
the water by practitioners in an extralabel fashion for reduction
of losses associated with S. suis. These drugs were not evalu-
ated in this study.
Ceftiofur hydrochloride (Excenel) injections were the most
effective in controlling mortality associated with PRRSV and
S. suis coinfection. Mortality was reduced from 63% in positive
controls to 9% in the ceftiofur group (P , 0.05). Ceftiofur is
approved for treatment of swine bacterial respiratory disease
associated with Actinobacillus pleuropneumoniae, Pasteurella
multocida, Salmonella choleraesuis, and S. suis serotype 2. We
used the recommended treatment protocol of three consecu-
tive daily injections and the highest recommended dose (5
mg/kg). Although ceftiofur hydrochloride was clearly the most
TABLE 4. PRRSV isolation from BAL and serum specimensc
Group
No. of pigs from
which PRRSV was
isolated from BALa
specimens/total
no. of pigs
No. of pigs from which PRRSV was isolated
from serum specimensb at indicated
times/total no. of pigs
0 DPI 7 DPI 14 DPI 28 DPI
1 0/11 A 0/11 A 0/11 A 0/11 A 0/11 A
2 8/11 C 0/11 A 11/11 B 4/4 B 2/4 A, B
3 7/11 C 0/11 A 11/11 B 11/11 B 1/6 A, B
4 9/11 C 0/11 A 10/11 B 6/7 B 3/5 B
5 2/11 A, B 0/11 A 11/11 B 9/11 B 0/10 A
6 4/10 B, C 0/10 A 10/10 B 7/7 B 3/6 B
7 8/11 C 0/11 A 11/11 B 5/6 B 0/2 C
a Bronchoalveolar lavage fluid collected at necropsy.
b Sera was collected from the remaining live pigs at 0, 7, 14, and 28 DPI.
c Within each column, values followed by letters (A, B, C, and D) are signif-
icantly different from other values followed by a different letter(s) (P , 0.05).
TABLE 5. Isolation of S. suis type 2 from tissues and bloode
Group
No. of pigs from which S. suis type 2 was isolated at indicated site/total no. of pigs
Tissuesa Bloodb
CNS URTc Lung Joint Pl, Pt, and/or Pcd Days 1–3 Necropsy
1 1/11 A 1/11 A 0/11 A 0/11 A 0/11 A 0/6 A 0/11 A
2 5/11 A, B 2/11 A 1/11 A 3/11 A, B 3/11 A, B 1/6 A 6/11 C
3 4/11 A, B 2/11 A 2/11 A 5/11 B 4/11 A, B 2/6 A 4/11 A, B, C
4 4/11 A, B 2/11 A 3/11 A 2/11 A, B 5/11 B 0/6 A 5/11 A, B, C
5 1/11 A 0/11 A 1/11 A 1/11 A, B 1/11 A, B 1/6 A 1/11 A, B
6 3/10 A, B 2/10 A 1/10 A 2/10 A, B 3/10 A, B 2/6 A 3/10 A, B
7 7/11 B 3/11 A 3/11 A 3/11 A, B 4/11 A, B 3/6 A 7/11 C
a Tissues collected at the time of necropsy.
b Blood collected on days 1, 2, and 3 after S. suis challenge and at necropsy.
c URT, upper respiratory tract (turbinate or trachea).
d Pl, Pt, and Pc, pleura, peritoneum, and pericardium, respectively.
e Within each column, values followed by letters (A, B, C, and D) are significantly different from other values followed by a different letter(s) (P , 0.05).
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effective treatment, it may be difficult to get pig producers to
comply with administering three consecutive daily injections of
the drug, and the cost of Excenel may be prohibitive.
The challenge isolate used in this experiment was suscepti-
ble to all the antimicrobials used based on results of breakpoint
susceptibility tests and microbroth dilution determinations of
MICs. The health of the pigs improved considerably during
treatment with all the antimicrobials; however, recrudescence
of disease shortly after cessation of treatment was observed in
many of the pigs in the penicillin and tiamulin treatment
groups. This suggests that these antimicrobials did not effec-
tively clear the S. suis infection from all pigs in these groups.
The increased survivability observed in the group treated with
ceftiofur might simply be attributed to better efficacy of clear-
ance of S. suis from blood, internal tissues, and mucosal sur-
faces. S. suis type 2 was recovered from only one pig in the
ceftiofur group, and that was the only pig in the group that died
prior to the termination of the study. It is also possible that the
penicillin and tiamulin treatment protocols selected for S. suis
isolates that were less susceptible to those antimicrobials and
the more resistant isolates subsequently induced disease and
mortality. Unfortunately, the isolates recovered from the pigs
at necropsy were later discarded, so posttreatment antimicro-
bial susceptibility profiles could not be obtained.
The mortality in the group vaccinated with the autogenous
S. suis vaccine was 40% compared to 63% in the untreated
positive controls (P . 0.05). Results were not significantly
better than those with penicillin, tiamulin, or RespPRRS/Re-
pro modified live-virus vaccination. The use of autogenous
bacterins for the control of S. suis-associated disease is com-
mon; however, the efficacy of the products remains controver-
sial. In the diagnostic laboratory at Iowa State University, we
routinely forward S. suis isolates from field cases to commercial
laboratories at the request of referring veterinarians for pro-
duction of autogenous vaccines. Based on the results from this
study, the use of autogenous S. suis bacterins may not be an
effective approach for controlling S. suis in pigs coinfected with
PRRSV. It is possible that an S. suis autogenous bacterin may
have better efficacy in a natural-exposure field situation than in
the artificial high-dose challenge exposure used in this exper-
iment.
Mortality in the group vaccinated with RespPRRS/Repro
modified live-virus vaccine was 81% compared to 63% in the
untreated positive controls (P . 0.05). The data from our
previous model development experiments (14) suggest that
intranasal administration of RespPRRS/Repro modified live-
virus vaccine may exacerbate S. suis-induced disease and in-
crease susceptibility to S. suis challenge. The data from the
current experiment further support our previous observations.
Veterinarians should carefully evaluate the safety and efficacy
of using modified live-virus vaccines in swine production sys-
tems where S. suis-associated disease is endemic. It is possible
that the RespPRRS/Repro vaccine may have better efficacy
with a different strain of challenge virus or in a natural-expo-
sure situation rather than in the artificial high-dose challenge
exposure used in this experiment. A longer time between
PRRSV vaccination and PRRSV challenge may increase the
efficacy as well. However, challenge dose, strain, and timing
often cannot be controlled or predicted under field conditions.
Of the regimens tested in this model, intramuscular admin-
istration of ceftiofur hydrochloride appears to be the best op-
tion for minimizing disease associated with PRRSV and S. suis
coinfection. This work should be extended to test the efficacy
of different treatment intervals of the above-named drugs and
to test additional antibiotics commonly used in the field such as
ampicillin, amoxicillin, and cefalexin. Other commercial and
experimental PRRSV and S. suis vaccines can also be tested
with this model.
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